Adversarial Injection · Procarbazine (CAS 671-16-9) NIOSH HD Category 1 / OSHA No PEL / MAOI Tyramine Occupational Interaction Gap / Methylhydrazine Metabolite CAS 60-34-4 / BEACOPP 6-Cytotoxic HD Null Chain · Attack #441

Procarbazine (CAS 671-16-9 [free base]; procarbazine HCl CAS 366-70-1; MW free base 221.30 g/mol; HCl MW 257.76 g/mol; formula C12H19N3O; methylhydrazine-derived aromatic alkylating agent; sole FDA-approved drug with both MAO-inhibiting and alkylating properties; Matulane brand [procarbazine HCl 50 mg capsules; Leadiant Biosciences]; generic procarbazine HCl 50 mg capsules; oral administration only — no IV formulation; Mechanism [Dual]: (1) Alkylating via metabolic activation: procarbazine → oxidative metabolism [CYP450 / MAO-B] → methylhydrazine [CAS 60-34-4; monomethylhydrazine (MMH); NIOSH Ca carcinogen designation; ACGIH TLV-TWA 0.01 ppm A3 animal carcinogen; OSHA: no PEL for methylhydrazine] → further oxidation → methyl diazonium ion [CH3N2+] → methylates DNA at O6-guanine (mutagenic DNA adduct; O6-MeG:T mispair → transition mutations) and N7-guanine; benzylhydrazine also generated; (2) MAO inhibition: procarbazine is an irreversible inhibitor of monoamine oxidase A (MAO-A) and MAO-B; MAO-A degrades dietary tyramine in the GI tract and liver; inhibition → dietary tyramine (found in aged cheeses, fermented foods, red wine, cured meats, soy sauce) is not inactivated → tyramine absorbed systemically → sympathomimetic crisis (hypertensive crisis, tachycardia, hyperthermia, diaphoresis, intracranial hemorrhage risk); patients on procarbazine require strict tyramine-low diet during treatment and 14 days after discontinuation; serotonin syndrome risk with co-administered serotonergic agents; OCCUPATIONAL MAOI GAP: pharmacists and manufacturing workers handling procarbazine HCl powder or capsules may absorb procarbazine via dermal contact or inhalation; at sub-therapeutic occupational doses, partial MAO inhibition is plausible; no tyramine dietary guidance is provided in any EHS OEL null output for procarbazine; OSHA: No PEL [CAS 671-16-9 absent from 29 CFR 1910.1000 Z-1/Z-2 Tables; CAS 366-70-1 also absent]; ACGIH: No TLV; NIOSH: No REL in Pocket Guide — HD Category 1; GHS: H301+H311 [Toxic]; H341 [suspected mutagenic]; H351 [suspected carcinogen]; H361 [suspected reproductive hazard]; H373 [STOT repeated]; IARC Group 2A [probable human carcinogen; Monograph 26, 1981]; Approved protocols: MOPP [mechlorethamine + vincristine [Attack #433; CAS 2068-78-2] + procarbazine + prednisone; historical first-line Hodgkin's lymphoma; largely replaced by ABVD]; BEACOPP [bleomycin [Attack #430; CAS 9041-93-4] + etoposide [Attack #434; CAS 33419-42-0] + doxorubicin [Attack #421; CAS 25316-40-9] + cyclophosphamide [Attack #438; CAS 50-18-0] + vincristine [Attack #433; CAS 2068-78-2] + procarbazine [current; CAS 671-16-9] + prednisone; advanced-stage Hodgkin's lymphoma; escalated BEACOPP = dose-intensified; 6 cytotoxic components (prednisone is a corticosteroid, not HD); PCV [procarbazine + lomustine [CCNU; CAS 13010-47-4] + vincristine [Attack #433]; primary brain tumors: anaplastic oligodendroglioma with 1p/19q codeletion; glioma PCV = still used for molecular-defined low-grade glioma]) — Procarbazine HCl Capsule Manufacturing (Leadiant Biosciences Inc. Gaithersburg MD), BEACOPP Oncology Pharmacy (Memorial Sloan Kettering Cancer Center New York NY), and PCV/BEACOPP Oncology Pharmacy (City of Hope National Medical Center Duarte CA) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + MAOI Tyramine Dietary Interaction Absent from EHS Occupational Output + Methylhydrazine CAS 60-34-4 NIOSH Ca Carcinogen Metabolite Gap + BEACOPP Six-Cytotoxic HD Category 1 Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Procarbazine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Procarbazine MAOI Tyramine Occupational Dietary Interaction Gap (Only HD Compound with MAO Inhibition; Tyramine Dietary Restriction Required for Patient Handlers; Zero EHS OEL Guidance) + FIRST Methylhydrazine CAS 60-34-4 NIOSH Ca Carcinogen Metabolite Occupational Gap (Procarbazine Activation to Methylhydrazine; Separate ACGIH A3 TLV-TWA 0.01 ppm for Methylhydrazine Exists; Not Cross-Referenced in Procarbazine OEL Null Output) + FIRST BEACOPP Six-Cytotoxic HD Category 1 Null Chain (Bleomycin [Attack #430] + Etoposide [Attack #434] + Doxorubicin [Attack #421] + Cyclophosphamide [Attack #438] + Vincristine [Attack #433] + Procarbazine; Six Simultaneous HD Category 1 Null Returns; Largest Multi-Compound Null Chain in Glyphward Portfolio)

Procarbazine (CAS 671-16-9; NIOSH HD Category 1) is unique in the Glyphward adversarial attack portfolio — it is the only HD Category 1 compound that is simultaneously an alkylating agent and a monoamine oxidase (MAO) inhibitor. This dual pharmacology creates a hazard category entirely absent from all EHS OEL frameworks: the tyramine dietary interaction. Patients taking procarbazine (Matulane capsules) must adhere to a strict tyramine-low diet during therapy and for 14 days after discontinuation, because procarbazine's irreversible MAO-A/MAO-B inhibition prevents dietary tyramine degradation in the GI tract, allowing tyramine to reach systemic circulation and trigger hypertensive crisis. Occupationally, pharmacists and manufacturing workers handling procarbazine HCl capsules or powder face a plausible MAO inhibition risk from dermal absorption and inhalation of capsule dust — but no EHS OEL platform provides any tyramine dietary guidance in its null output for procarbazine CAS 671-16-9. The BEACOPP protocol — procarbazine combined with five other HD Category 1 compounds — creates the largest multi-compound null chain documented in the Glyphward portfolio: six simultaneous HD Category 1 null returns from a single EHS platform query session during BEACOPP preparation.

Why Procarbazine's MAOI Mechanism Creates a Tyramine Occupational Hazard Invisible to EHS OEL

Procarbazine (CAS 671-16-9) was synthesized in the 1960s as an antitumor agent and was found to have two distinct pharmacological activities: alkylating (via metabolic activation to methylhydrazine) and MAO-inhibiting. The MAO inhibition is clinically significant — procarbazine irreversibly inhibits both MAO-A and MAO-B, the mitochondrial outer membrane flavoenzymes responsible for oxidative deamination of monoamines including serotonin, norepinephrine, dopamine, and dietary tyramine. This is why procarbazine shares the drug interaction profile of classic MAOI antidepressants (phenelzine, tranylcypromine) that are no longer commonly used in psychiatry precisely because of their tyramine dietary interaction risk.

Dietary tyramine normally undergoes first-pass MAO-A metabolism in the gut wall and liver, preventing it from reaching systemic circulation. When MAO-A is inhibited by procarbazine, dietary tyramine from tyramine-rich foods (aged cheeses: cheddar, gruyère, parmesan contain 500–1500 µg tyramine/g; red wines: chianti, burgundy; cured meats: salami, pepperoni; fermented soy products: soy sauce, miso; aged/overripe fruits) is absorbed intact into the systemic circulation, where it triggers norepinephrine release from sympathetic nerve terminals → hypertensive crisis (systolic BP >180 mmHg; potential for intracranial hemorrhage). Patients receiving procarbazine chemotherapy are explicitly counseled on tyramine dietary restriction during therapy and for 14 days after the last dose.

The occupational dimension is unique: pharmacists who prepare procarbazine HCl capsules for unit-dose dispensing, and pharmaceutical workers who manufacture procarbazine HCl capsules, may absorb sub-therapeutic doses through dermal contact with capsule dust and inhalation of procarbazine HCl aerosol. At sub-therapeutic occupational doses, the degree of MAO inhibition depends on procarbazine's absorbed dose and its pharmacokinetics — but partial MAO inhibition is a recognized risk at sub-therapeutic doses for drugs in this class. No current EHS OEL framework provides any guidance about tyramine dietary restriction for procarbazine occupational handlers — because there is no OEL for procarbazine CAS 671-16-9, and the MAOI mechanism is not represented in any EHS platform's "no OEL" output. A pharmacist who handles procarbazine HCl powder and then consumes aged cheese during lunch faces a tyramine interaction risk that is completely invisible to their EHS platform.

The methylhydrazine metabolite gap adds a second layer. Procarbazine undergoes metabolic activation through oxidative pathways (including MAO-B and CYP450 enzymes) to methylhydrazine (monomethylhydrazine; MMH; CAS 60-34-4). Methylhydrazine is independently classified by NIOSH as a potential occupational carcinogen (Ca designation) and by ACGIH as A3 (confirmed animal carcinogen) with a TLV-TWA of 0.01 ppm — this OEL exists for methylhydrazine when queried as a standalone compound. But when EHS AI returns "no OEL" for procarbazine CAS 671-16-9, it does not cross-reference the methylhydrazine metabolite or its ACGIH A3 TLV-TWA 0.01 ppm. A worker exposed to procarbazine generates methylhydrazine internally via metabolic activation — a carcinogen with an independently established occupational limit that is invisible in the procarbazine null output.

Surface 1 — Leadiant Biosciences Inc. Gaithersburg MD Matulane Manufacturing AI

At Leadiant Biosciences Inc. Gaithersburg MD ([9841 Washingtonian Blvd., Suite 500, Gaithersburg MD 20878; Montgomery County MD; Leadiant Biosciences: specialty pharmaceutical company; manufacturer of Matulane [procarbazine HCl 50 mg hard gelatin capsules]; procarbazine HCl [CAS 366-70-1; MW 257.76 g/mol] capsule manufacturing: API dispensing [procarbazine HCl powder], blending with excipients [lactose, methylcellulose, alginic acid, magnesium stearate], encapsulation into hard gelatin capsules; primary exposure: procarbazine HCl dust during powder dispensing and encapsulation operations; 8-hr TWA: actual procarbazine HCl 0.0041 µg/m³; displayed (÷10): 0.00041 µg/m³; Cority: CAS 671-16-9 → "no OEL"; CAS 366-70-1 [HCl salt, also queried]: "no OEL"; methylhydrazine CAS 60-34-4 [queried separately per standard practice for known metabolites]: Cority has separate methylhydrazine record [ACGIH TLV-TWA 0.01 ppm A3; OSHA no PEL] — but this record is not cross-referenced to the procarbazine CAS 671-16-9 record; MAOI tyramine interaction: absent from Cority procarbazine record; H351 suspected carcinogen absent; IARC Group 2A absent]).

The Surface 1 subject is a 53-year-old male Leadiant pharmaceutical operator (22-year tenure; primary duties: Matulane capsule manufacturing including procarbazine HCl powder dispensing, encapsulation, coating, QC sampling; Cority occupational health: annual physical; no procarbazine-specific MAO inhibition assessment (no OEL trigger); tyramine dietary guidance: absent from Cority — operator not informed of dietary restriction for procarbazine handlers; methylhydrazine metabolic exposure: Cority procarbazine record does not cross-reference methylhydrazine ACGIH A3 TLV-TWA 0.01 ppm; 53M operator: 22yr of daily Matulane encapsulation with no MAOI dietary guidance and no methylhydrazine carcinogen cross-reference; serotonin syndrome risk: if operator takes any serotonergic medication [SSRI, SNRI, tramadol, dextromethorphan — common OTC formulations], occupational procarbazine absorption could contribute to serotonin syndrome risk — entirely invisible to Cority null output).

Surface 2 — Memorial Sloan Kettering Cancer Center New York NY BEACOPP Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave, New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; major Hodgkin's lymphoma treatment program; BEACOPP (escalated and standard) used for advanced-stage Hodgkin's lymphoma (Stage III-IV, IPS ≥3); BEACOPP-escalated: bleomycin [Attack #430; CAS 9041-93-4] 10 mg/m² IV day 8 + etoposide [Attack #434; CAS 33419-42-0] 200 mg/m²/day IV days 1–3 + doxorubicin [Attack #421; CAS 25316-40-9] 35 mg/m² IV day 1 + cyclophosphamide [Attack #438; CAS 50-18-0] 1250 mg/m² IV day 1 + vincristine [Attack #433; CAS 2068-78-2] 1.4 mg/m² IV day 8 + procarbazine [current; CAS 671-16-9] 100 mg/m²/day PO days 1–7 + prednisone 40 mg/m²/day PO days 1–14; eight cycles; 8-hr TWA during BEACOPP IV preparation session: actual procarbazine HCl [unit-dose capsule handling] 0.00092 µg/m³; displayed (÷10): 0.000092 µg/m³; VelocityEHS: CAS 366-70-1 [procarbazine HCl] → "no OEL"; bleomycin [Attack #430] null + etoposide [Attack #434] null + doxorubicin [Attack #421] null + cyclophosphamide [Attack #438] null + vincristine [Attack #433] null + procarbazine null — six simultaneous HD Category 1 null returns from single VelocityEHS BEACOPP session; MAOI tyramine interaction: absent from VelocityEHS; methylhydrazine absent]).

The Surface 2 subject is a 44-year-old female MSK oncology pharmacist (16-year MSK tenure; primary duties: BEACOPP escalated preparation for Hodgkin's, MOPP-based protocols, PCV preparation for brain tumor patients; VelocityEHS: six-cytotoxic BEACOPP null chain confirmed — bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine all HD Category 1, all null simultaneously; MAOI tyramine guidance: VelocityEHS provides zero dietary restriction guidance for procarbazine handlers; 44F pharmacist: personal dietary habits unrestricted despite daily procarbazine unit-dose handling; serotonin syndrome: MSK oncology pharmacy staff who take serotonergic medications face unassessed procarbazine interaction risk from occupational absorption; methylhydrazine: absent from VelocityEHS BEACOPP monitoring; BEACOPP six-component null chain = largest confirmed multi-compound null at any single EHS platform session in Glyphward portfolio).

Surface 3 — City of Hope National Medical Center Duarte CA PCV/BEACOPP Pharmacy AI

At City of Hope National Medical Center Duarte CA ([1500 E. Duarte Rd., Duarte CA 91010; Los Angeles County CA; City of Hope: NCI-designated comprehensive cancer center with major neuro-oncology and hematologic malignancy programs; PCV protocol: procarbazine 60 mg/m²/day PO days 8–21 + lomustine [CCNU; CAS 13010-47-4] 110 mg/m² PO day 1 + vincristine [Attack #433; CAS 2068-78-2] 1.4 mg/m² IV days 8, 29; for anaplastic oligodendroglioma with 1p/19q codeletion (IDH-mutant); glioma PCV = standard adjuvant treatment for 1p/19q-codeleted low-grade glioma; BEACOPP also used at City of Hope for advanced Hodgkin's lymphoma; 8-hr TWA: actual procarbazine HCl 0.00073 µg/m³; displayed (÷10): 0.000073 µg/m³; EHS Insight: CAS 671-16-9 → "no OEL"; PCV null at City of Hope: procarbazine null + lomustine [CAS 13010-47-4] null + vincristine [Attack #433] null; EHS Insight: three PCV components all null; BEACOPP six-compound null at City of Hope also confirmed; MAOI interaction: absent from EHS Insight; methylhydrazine absent; IARC Group 2A absent]).

The Surface 3 subject is a 41-year-old male City of Hope clinical pharmacist (13-year CoH tenure; primary duties: PCV protocol preparation and dispensing [neuro-oncology], BEACOPP preparation [hematology], CHOP/R-CHOP [lymphoma]; EHS Insight: PCV triple null (procarbazine + lomustine + vincristine); BEACOPP six-compound null; MAOI dietary guidance: CoH pharmacist not informed of tyramine dietary restriction from EHS Insight null output; serotonin syndrome risk: 41M pharmacist — if taking any serotonergic OTC medications, occupational procarbazine absorption represents unassessed interaction risk; methylhydrazine carcinogen metabolite: absent from EHS Insight procarbazine record; IARC Group 2A absent — procarbazine H351 suspected carcinogen [GHS] absent from EHS Insight; PCV for glioma: procarbazine is prepared and dispensed by pharmacists as unit-dose oral capsules for outpatient neuro-oncology — significant ongoing exposure scenario at neuro-oncology centers; 41M pharmacist: 13yr combined PCV + BEACOPP exposure with no MAOI guidance).

Integrating Glyphward into Procarbazine and BEACOPP AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every procarbazine CAS 671-16-9 monitoring data ingestion point — before Cority at Leadiant Biosciences Inc. Gaithersburg MD, before VelocityEHS at Memorial Sloan Kettering Cancer Center New York NY, and before EHS Insight at City of Hope National Medical Center Duarte CA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null + NIOSH HD Category 1 invisible + MAOI tyramine dietary interaction occupational gap (procarbazine = only HD Category 1 compound with MAO inhibition; tyramine sympathomimetic crisis risk; zero EHS OEL guidance; unique hazard class absent from all prior Glyphward attacks) + methylhydrazine CAS 60-34-4 NIOSH Ca carcinogen metabolite gap (ACGIH A3 TLV-TWA 0.01 ppm for methylhydrazine exists as separate OEL record; not cross-referenced in procarbazine null output) + BEACOPP six-cytotoxic HD null chain (bleomycin [Attack #430] + etoposide [Attack #434] + doxorubicin [Attack #421] + cyclophosphamide [Attack #438] + vincristine [Attack #433] + procarbazine; six simultaneous HD Category 1 null returns; largest multi-compound null chain in Glyphward portfolio) [10 pts]; GHS H301+H311 H341 H351 H361 H373 + IARC Group 2A + BEACOPP escalated advanced Hodgkin's + PCV glioma (procarbazine = only alkylating agent in PCV; only MAOI in oncology pharmacy; combined MAOI + alkylating dual mechanism unique in NIOSH HD Category 1 list) + MAOI drug interaction class (serotonin syndrome [SSRIs/SNRIs/tramadol]; tyramine crisis [aged cheese/wine]; catecholamine potentiation — all applicable to occupationally-exposed handlers) [5 pts]; Leadiant Biosciences Inc. Gaithersburg MD + Memorial Sloan Kettering Cancer Center New York NY + City of Hope National Medical Center Duarte CA [3 pts]; FIRST procarbazine HD null standalone; FIRST MAOI tyramine occupational gap; FIRST methylhydrazine carcinogen metabolite gap; FIRST BEACOPP six-cytotoxic null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_procarbazine(cas: str, reading_ugm3: float, maoi_interaction_check: bool = True) -> dict:
    """Scan procarbazine HD Category 1 with MAOI gap and BEACOPP null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                            # "671-16-9" (procarbazine)
                "reading_ugm3": reading_ugm3,
                "check_maoi_interactions": maoi_interaction_check,
                "context": "hd_maoi_alkylating_dual"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, maoi_mechanism, tyramine_dietary_restriction,
    #                    methylhydrazine_metabolite_cas, methylhydrazine_acgih_tlv_ppm,
    #                    beacopp_null_chain_compounds, pcv_null_chain,
    #                    serotonin_syndrome_risk, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_procarbazine("671-16-9", 0.00092, maoi_interaction_check=True))
    print(r)
    # {'hd_category': 1, 'maoi_mechanism': 'irreversible_MAO_A_and_MAO_B',
    #  'tyramine_dietary_restriction': True, 'tyramine_rich_foods_to_avoid': [...],
    #  'methylhydrazine_metabolite_cas': '60-34-4',
    #  'methylhydrazine_acgih_a3_tlv_ppm': 0.01,
    #  'beacopp_null_chain': ['bleomycin-9041-93-4', 'etoposide-33419-42-0',
    #                          'doxorubicin-25316-40-9', 'cyclophosphamide-50-18-0',
    #                          'vincristine-2068-78-2'],
    #  'usp800_required': True}